BioNTech Advances Oncology Pipeline and Strengthens 2025 Financial Outlook
MAINZ, Germany, November 3, 2025 — BioNTech SE (Nasdaq: BNTX) reported its third quarter 2025 financial results, highlighting significant...
Oncology
Advertisement
Aptose to Present Promising Tuspetinib AML Data at 2025 ASH Meeting
SAN DIEGO and TORONTO, November 3, 2025 — Aptose Biosciences Inc. (TSX: APS), a clinical-stage precision oncology company, announced...
FDA Grants Interchangeability for Celltrion’s Denosumab Biosimilars
Incheon, South Korea, October 30, 2025 — Celltrion, Inc., a global biopharmaceutical company specializing in biosimilars and innovative biologics,...
EU Approves KEYTRUDA for Resectable Head & Neck Cancer
Kenilworth, N.J., October 29, 2025— Merck & Co., Inc. (NYSE: MRK), known as MSD outside the U.S. and Canada,...
AB Science Secures €2.8 Million in Private Placement to Advance Clinical Pipeline
PARIS, October 17, 2025 AB Science S.A., a biopharmaceutical company focused on discovering, developing, and marketing protein kinase inhibitors,...
Advertisements
FDA Fast Tracks Enterome’s OncoMimics™ Cancer Immunotherapy EO2463
Paris, France – October 16, 2025 – The U.S. Food and Drug Administration (FDA) has granted Fast Track designation...
Pfizer’s TUKYSA Shows Strong Benefit in First-Line HER2+ Breast Cancer
NEW YORK, Oct. 14, 2025 – Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 HER2CLIMB-05...
TransCode Reports Positive Phase 1a Results for TTX-MC138 in Metastatic Cancer
BOSTON, Massachusetts, October 14, 2025 — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced encouraging preliminary data from its completed...
BeOne Medicines’ Sonrotoclax Gets FDA Breakthrough Status
October 13, 2025 | USA – BeOne Medicines, a clinical-stage biopharmaceutical company, announced that its investigational drug Sonrotoclax has...
AstraZeneca Unveils Landmark Cancer Trial Results at ESMO 2025
Madrid, Spain – October 11, 2025 – AstraZeneca presented groundbreaking clinical trial results from four major Phase III studies...
Advertisement
